Our Blog

Johnson & Johnson Involved in Kickbacks

January 20, 2010

The AAJ cited a recent NYT article today that Johnson & Johnson paid kickbacks to the largest nursing home pharmacy to increase the number of elderly patients that ingest its medications. The complaint was filed by the US attorney in Boston. “The complaint alleges that Omnicare received “tens of millions of dollars…to buy and recommend Risperdal [risperidone], ‘as well as “prescription pain relievers Duragesic and Ultram, and the antibiotic Levaquin’.” The kickbacks were to Omnicare were disguised as grants or educational funds to influence doctors to have prescriptions switched. Apparently “J&J paid Omnicare rebates for switching prescriptions. Under federal law, rebates are legal unless Medicaid does not receive the same benefit. The complaint alleges that J&J disguised its rebates to Omnicare as physician-prescriber-data payments in order to avoid reporting them.” The complaint alleges that J&J disguised its rebates to Omnicare as physician-prescriber-data payments to avoid reporting them. Once again the prescription drug companies are placing their concern for profits before the best interest of the patients.

Request Your Free Consultation

Get the answers and support you need. Our friendly and experienced Buffalo personal injury lawyers will take the time to understand your case, explain your options, and guide you every step of the way.

Our Practice Areas

Read More Articles

Ohio Court Finds Employment Agreement Unenforceable That Requires Attorney to Return 95% of Fees

Toy Recall

Today, the Pittsburgh Post Gazette reported, that due to high levels of lead, “Team Work Trading” is recalling approximately 1, 400 children’s animal masks and pendants. These masks and pendants were sold from November 2008 – March 2009.

Read Blog
Ohio Court Finds Employment Agreement Unenforceable That Requires Attorney to Return 95% of Fees

Pfizer Agrees to $2.3 Billion Settlement

The CBS Evening News and the AAJ are reporting that Pfizer was hit with $2.3 Billion in fines for for violating federal drug marketing rules. Pfizer was accused of promoting the pain medication Bextra for uses that were not approved.

Read Blog